Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI scans may reveal which throat cancer patients need stronger treatment

NCT ID NCT07797738

Diagnosis Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This study tests whether special MRI scans can predict how well HPV-positive throat cancer responds to standard chemotherapy and radiation. Researchers will scan 30 adults before treatment and track their outcomes. The goal is to see if MRI patterns can identify low-risk patients who might need less intense therapy and high-risk patients who could benefit from stronger or targeted treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magnetic Resonance Imaging (MRI) with contrast dye
What this could lead to
If MRI patterns predict treatment response, doctors could tailor therapy: lower doses for low-risk patients and more aggressive or targeted treatments for high-risk patients.
What could go wrong
This is a small, early study. The MRI measurements may not reliably predict outcomes, and the results may not apply to all patients. More research would be needed before this becomes a standard tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult population (≥18 years) of both genders * Biopsy confirmed diagnosis of OPSCC * Known HPV status as determined by p16 immunohistochemistry (p16 positivity defined as \>70% of carcinoma cells showing nuclear reactivity) or polymerase chain reaction (PCR) sequencing * Prior to any treatment except for incisional or excisional biopsies * T0 to T4, N1 to N3, M0 (American Joint Committee on Cancer, 8th edition) * A willingness to undergo multiple phlebotomy (blood withdrawal) during standard CRT for liquid biopsy analyses. Exclusion Criteria: * HPV- negative OPSCC * Presence of distant metastatic (M1) disease * Pregnancy * Existence of significant co-morbidities at baseline which would prevent standard CRT treatment * Implanted cardiac pacemaker or defibrillator, programmable shunts, deep brain stimulator, other implanted electronic devices which may be contraindicated for 3T MRI * Presence of significant hemorrhage in and around the tumor bed that may potentially degrade the image quality * Significant claustrophobia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection oropharynx squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV HPV positive oropharyngeal squamous cell carcinoma Oropharyngeal squamous cell carcinoma (opscc)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.